Answers are grounded in this paper and cite their sources.
Identifies therapeutic vulnerabilities in acute myeloid leukemia, suggesting a new approach for personalized treatment.
Acute myeloid leukemia (AML) is characterized by profound biological and clinical heterogeneity, where traditional mutation-centric frameworks often fail to fully capture the complex interplay between genomic drivers and functional phenotypes. In this study, we employed Multi-Omic Factor Analysis (MOFA) to integrate transcriptomic, mutational, pharmacological, and clinical data from a focused cohort of treatment-naïve de novo AML specimens. By utilizing a Bayesian framework, we identified nine latent factors that collapse high-dimensional data into distinct biological axes, explaining the majority of variance in the transcriptomic (54.5%) and clinical (23.7%) modalities. Our results characterized Factor 1 as a monocytic differentiation axis defined by high expression of mature myeloid markers such as CD14 and S100A8/9. Furthermore, the integration of MOFA-derived factors with the European LeukemiaNet (ELN) 2022 risk classification improved predictive accuracy, increasing the Harrell’s C-index from 0.66 to 0.72. These findings conclude that "molecularly silent" variance—biology not captured by somatic mutations alone—is a critical determinant of chemotherapy response and clinical outcome. Ultimately, this work provides a robust framework for transitioning toward a functional, multi-omic approach for personalized therapeutic selection and more precise risk assessment in AML.
No takes yet. Share an insight, caveat, or question.
Bahar Tercan (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: